Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological ...

A new, incision-free technique developed at UVA Health to treat debilitating brain lesions called cerebral cavernous ...

A new, incision-free technique developed at UVA Health to treat debilitating brain lesions called cerebral cavernous ...

Reduced levels of the TDP-43 protein have been linked to brain diseases like Alzheimer’s, frontotemporal dementia and ALS, ...

Publication of significant peer-reviewed research highlighting the ability of alkaline phosphatase (ALPL) to transport AAV capsids across the blood-brain barrier, validating Voyager’s gene ...

Hevin reverses cognitive decline in mice by improving neuronal connections, without affecting amyloid plaque levels.

UVA Health researchers developed a non-invasive focused ultrasound method with microbubbles that stops the growth of cerebral cavernous malformations (CCMs) in mice. The approach temporarily opens the ...

BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today announced that the investigational B7-H3 ...

Researchers developed a biomimetic nanovesicle that crosses the blood-brain barrier, degrades DNA repair proteins, and ...

A new, incision-free technique developed at UVA Health to treat debilitating brain lesions called cerebral cavernous malformations, or cavernomas, has shown great promise in early testing, halting the ...